Drug Profile
VX 241
Alternative Names: VX-241Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in Pain in USA
- 23 Feb 2017 Vertex Pharmaceuticals has patent protection for VX 241 in USA and countries outside USA (Vertex Pharmaceuticals form 10-K, filed in February 2017)
- 22 Dec 2015 Preclinical trials in Pain in USA (unspecified route) prior to October 2015